Tucatinib Continuation Study

Sponsor
Pfizer
Study ID
NCT07768358
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • tucatinib — DRUG
    150 - 300 mg, by mouth, twice a day

Study Details

The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.

Key Dates

First listed
Aug 17, 2026
Start date
Aug 24, 2026
Status verified
Aug 2026
Primary completion
Mar 13, 2032
Completion
Mar 13, 2032

Study Design

Enrollment
175 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: tucatinib
    150 - 300 mg, by mouth, twice a day

Primary Outcome Measure

To monitor the safety and tolerability of tucatinib [ Time Frame: Up to approximately 5 years ]

Central Contacts

Find similar trials

Nationwide
Cervical cancer trialsColorectal cancer trialsBreast cancer trialsBladder cancer trialsOncology trialsGynecologic oncology trialsWomen's health trialsGI oncology trialsBreast oncology trialsUrology trials

Related Studies